Forget rockets. Obesity is taking us to the moon. $vktx
$VKTX
AI SUMMARY — Viking Therapeutics ($VKTX) is positioned to benefit from the growing obesity treatment market, with potential blockbuster drugs that could rival GLP-1 competitors like Ozempic. Key risks include clinical trial failures, regulatory setbacks, and intense competition from established players with larger resources.
| TICKER | VKTX |
USER | u/kvara_17 |
| RATING |
BULLISH |
ENTRY |
$28.45
|
| POSITION |
351 sh
SYN
|
BOOK VAL |
$9985.95 |
| CURRENT |
$37.87 |
P&L % |
+33.11%
|
| CURR VAL |
$13292.37 |
P&L $ |
+3306.42
|